Pfizer Agreement Clause Samples
The "Pfizer Agreement" clause defines the specific contract or set of terms established between the parties and Pfizer. This clause typically outlines the rights, obligations, and responsibilities that each party has in relation to Pfizer, such as licensing arrangements, collaboration terms, or distribution rights. By clearly identifying and referencing the Pfizer Agreement, this clause ensures that all parties understand the governing terms and reduces the risk of misunderstandings or disputes regarding their relationship with Pfizer.
Pfizer Agreement. (a) To the extent that any rights granted to Beijing SL under this Agreement are Controlled by Gemphire pursuant to the Pfizer Agreement, (i) such rights are subject to the terms and conditions of the Pfizer Agreement, and (ii) Beijing SL agrees to comply with such terms and conditions.
(b) Without limiting the generality of Section 2.6(a), with respect to any rights granted to Beijing SL under this Agreement that are Controlled by Gemphire pursuant to the Pfizer Agreement (“Pfizer Sublicense Rights”), the Parties hereby agree that:
(i) Beijing SL shall not assign any of its Pfizer Sublicense Rights without the prior written consent of Pfizer;
(ii) Pfizer is a third party beneficiary under Beijing SL’s sublicense to the Pfizer Sublicense Rights, with the rights to enforce the applicable terms thereof;
(iii) Beijing SL shall not have the rights to grant any further sublicenses to the Pfizer Sublicense Rights in contravention with the terms of the Pfizer Agreement;
(iv) Beijing’s SL’s rights to any Pfizer Sublicense Rights shall terminate upon the termination of the Pfizer Agreement.
Pfizer Agreement. To the extent that the license granted by Company under Section 2.1 constitutes a sublicense under the rights granted to Company in the Pfizer Agreement, such license is subject to the terms, conditions, and limitations of the Pfizer Agreement.
Pfizer Agreement. In accordance with that certain Development, Commercialization and Supply Agreement between Auxilium and Pfizer Inc. (“Pfizer”), dated as of December 17, 2008, and the related pharmacovigilance agreement between Auxilium and Pfizer, Pfizer is responsible for maintaining the global safety database for the Product. The pharmacovigilance agreement to be entered into between the Parties pursuant to Section 5.6.1(a) shall provide for Auxilium communicating to Pfizer such information on behalf of Asahi as Pfizer requires for purposes of maintaining such global safety database in accordance with Laws and regulatory requirements; provided that, in the event a Governmental Authority or Laws or regulatory requirements require a separate pharmacovigilance agreement among Pfizer, Auxilium and Asahi, the Parties shall meet with Pfizer and agree upon a written pharmacovigilance agreement for exchanging adverse event and other safety information relating to the Product. Any such three-way pharmacovigilance agreement shall ensure that adverse event and other safety information is exchanged according to a schedule that will permit Pfizer, Asahi and Auxilium (and each of their designees and sublicensees, as applicable) to comply with Laws and regulatory requirements in their respective markets.